Brief Review of Hydroxychloroquine in Hospitalized COVID19 Patients— Mafham 2020

This is a brief audio review. In the article Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19 published, 2020 by Mafham and Colleagues, The outcomes and key points are as noted: The 28 day mortality was not lower in hospitalized patients with COVID 19 and were less likely to be discharged from the hospital alive when compared to the usual care group. 28 day mortality in the hydroxychloroquine treatment group compared in the usual care group was 27% versus 25%, rate ratio 1.09; 95% confidence interval 0.97 to 1.23, P=.15; Probability of discharge alive at 28 days was lower in the hydroxychloroquine treatment group 59.6% versus 62.9%, rate ratio 0.90 ; 95% confidence interval 0.83 to 0.98). This was a Randomized controlled trial, open label, [nonblinded] with 4716 patients who were patients who were hospitalized with COVID-19.

RECOVERY Collaborative Group, Horby P, Mafham M, Linsell L, Bell JL, Staplin N, Emberson JR, Wiselka M, Ustianowski A, Elmahi E, Prudon B, Whitehouse T, Felton T, Williams J, Faccenda J, Underwood J, Baillie JK, Chappell LC, Faust SN, Jaki T, Jeffery K, Lim WS, Montgomery A, Rowan K, Tarning J, Watson JA, White NJ, Juszczak E, Haynes R, Landray MJ. Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. N Engl J Med. 2020 Nov 19;383(21):2030-2040. doi: 10.1056/NEJMoa2022926. Epub 2020 Oct 8. PMID: 33031652; PMCID: PMC7556338.